Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 169

1.

Differentially expressed genes regulating the progression of ductal carcinoma in situ to invasive breast cancer.

Lee S, Stewart S, Nagtegaal I, Luo J, Wu Y, Colditz G, Medina D, Allred DC.

Cancer Res. 2012 Sep 1;72(17):4574-86. doi: 10.1158/0008-5472.CAN-12-0636. Epub 2012 Jul 2.

2.

Evidence that molecular changes in cells occur before morphological alterations during the progression of breast ductal carcinoma.

Castro NP, Osório CA, Torres C, Bastos EP, Mourão-Neto M, Soares FA, Brentani HP, Carraro DM.

Breast Cancer Res. 2008;10(5):R87. doi: 10.1186/bcr2157. Epub 2008 Oct 17.

3.

Gene expression profiling of tumour epithelial and stromal compartments during breast cancer progression.

Vargas AC, McCart Reed AE, Waddell N, Lane A, Reid LE, Smart CE, Cocciardi S, da Silva L, Song S, Chenevix-Trench G, Simpson PT, Lakhani SR.

Breast Cancer Res Treat. 2012 Aug;135(1):153-65. doi: 10.1007/s10549-012-2123-4. Epub 2012 Jun 21.

PMID:
22718308
4.

Molecular diversity in ductal carcinoma in situ (DCIS) and early invasive breast cancer.

Muggerud AA, Hallett M, Johnsen H, Kleivi K, Zhou W, Tahmasebpoor S, Amini RM, Botling J, Børresen-Dale AL, Sørlie T, Wärnberg F.

Mol Oncol. 2010 Aug;4(4):357-68. doi: 10.1016/j.molonc.2010.06.007. Epub 2010 Jun 26.

5.

Comparative analysis of loss of heterozygosity and expression profile in normal tissue, DCIS and invasive breast cancer.

Zikan M, Bohm J, Pavlista D, Cibula D.

Clin Transl Oncol. 2011 Sep;13(9):652-5. doi: 10.1007/s12094-011-0710-1.

PMID:
21865136
6.

Loss of interferon regulatory factor 5 (IRF5) expression in human ductal carcinoma correlates with disease stage and contributes to metastasis.

Bi X, Hameed M, Mirani N, Pimenta EM, Anari J, Barnes BJ.

Breast Cancer Res. 2011;13(6):R111. doi: 10.1186/bcr3053. Epub 2011 Nov 4.

7.

Role of deregulated microRNAs in breast cancer progression using FFPE tissue.

Chen L, Li Y, Fu Y, Peng J, Mo MH, Stamatakos M, Teal CB, Brem RF, Stojadinovic A, Grinkemeyer M, McCaffrey TA, Man YG, Fu SW.

PLoS One. 2013;8(1):e54213. doi: 10.1371/journal.pone.0054213. Epub 2013 Jan 23.

8.

Expression profiling of in vivo ductal carcinoma in situ progression models identified B cell lymphoma-9 as a molecular driver of breast cancer invasion.

Elsarraj HS, Hong Y, Valdez KE, Michaels W, Hook M, Smith WP, Chien J, Herschkowitz JI, Troester MA, Beck M, Inciardi M, Gatewood J, May L, Cusick T, McGinness M, Ricci L, Fan F, Tawfik O, Marks JR, Knapp JR, Yeh HW, Thomas P, Carrasco DR, Fields TA, Godwin AK, Behbod F.

Breast Cancer Res. 2015 Sep 17;17:128. doi: 10.1186/s13058-015-0630-z.

9.

Silencing of HSulf-2 expression in MCF10DCIS.com cells attenuate ductal carcinoma in situ progression to invasive ductal carcinoma in vivo.

Khurana A, McKean H, Kim H, Kim SH, mcguire J, Roberts LR, Goetz MP, Shridhar V.

Breast Cancer Res. 2012 Mar 12;14(2):R43.

10.

Analysis of stromal signatures in the tumor microenvironment of ductal carcinoma in situ.

Sharma M, Beck AH, Webster JA, Espinosa I, Montgomery K, Varma S, van de Rijn M, Jensen KC, West RB.

Breast Cancer Res Treat. 2010 Sep;123(2):397-404. doi: 10.1007/s10549-009-0654-0. Epub 2009 Dec 1.

11.

Classification of ductal carcinoma in situ by gene expression profiling.

Hannemann J, Velds A, Halfwerk JB, Kreike B, Peterse JL, van de Vijver MJ.

Breast Cancer Res. 2006;8(5):R61.

12.

Gene amplification in ductal carcinoma in situ of the breast.

Burkhardt L, Grob TJ, Hermann I, Burandt E, Choschzick M, Jänicke F, Müller V, Bokemeyer C, Simon R, Sauter G, Wilczak W, Lebeau A.

Breast Cancer Res Treat. 2010 Oct;123(3):757-65. doi: 10.1007/s10549-009-0675-8. Epub 2009 Dec 22.

PMID:
20033484
13.

S100A7 (psoriasin) expression is associated with aggressive features and alteration of Jab1 in ductal carcinoma in situ of the breast.

Emberley ED, Alowami S, Snell L, Murphy LC, Watson PH.

Breast Cancer Res. 2004;6(4):R308-15. Epub 2004 Apr 26.

14.

Identification of copy number alterations associated with the progression of DCIS to invasive ductal carcinoma.

Johnson CE, Gorringe KL, Thompson ER, Opeskin K, Boyle SE, Wang Y, Hill P, Mann GB, Campbell IG.

Breast Cancer Res Treat. 2012 Jun;133(3):889-98. doi: 10.1007/s10549-011-1835-1. Epub 2011 Nov 4.

PMID:
22052326
15.

Amplification of growth regulatory genes in intraductal breast cancer is associated with higher nuclear grade but not with the progression to invasiveness.

Glöckner S, Lehmann U, Wilke N, Kleeberger W, Länger F, Kreipe H.

Lab Invest. 2001 Apr;81(4):565-71.

PMID:
11304576
16.

HIN-1, a putative cytokine highly expressed in normal but not cancerous mammary epithelial cells.

Krop IE, Sgroi D, Porter DA, Lunetta KL, LeVangie R, Seth P, Kaelin CM, Rhei E, Bosenberg M, Schnitt S, Marks JR, Pagon Z, Belina D, Razumovic J, Polyak K.

Proc Natl Acad Sci U S A. 2001 Aug 14;98(17):9796-801. Epub 2001 Jul 31.

17.

Transcriptomic changes in human breast cancer progression as determined by serial analysis of gene expression.

Abba MC, Drake JA, Hawkins KA, Hu Y, Sun H, Notcovich C, Gaddis S, Sahin A, Baggerly K, Aldaz CM.

Breast Cancer Res. 2004;6(5):R499-513. Epub 2004 Jul 6. Erratum in: Breast Cancer Res. 2005;7(1):32.

18.

Gene expression profiling of the tumor microenvironment during breast cancer progression.

Ma XJ, Dahiya S, Richardson E, Erlander M, Sgroi DC.

Breast Cancer Res. 2009;11(1):R7. doi: 10.1186/bcr2222. Epub 2009 Feb 2.

19.

The urokinase-system in tumor tissue stroma of the breast and breast cancer cell invasion.

Hildenbrand R, Schaaf A.

Int J Oncol. 2009 Jan;34(1):15-23.

PMID:
19082473
20.

Early dysregulation of cell adhesion and extracellular matrix pathways in breast cancer progression.

Emery LA, Tripathi A, King C, Kavanah M, Mendez J, Stone MD, de las Morenas A, Sebastiani P, Rosenberg CL.

Am J Pathol. 2009 Sep;175(3):1292-302. doi: 10.2353/ajpath.2009.090115. Epub 2009 Aug 21.

Items per page

Supplemental Content

Write to the Help Desk